Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY:BDX)

195.40 -1.34 (-0.68%)
Streaming Delayed Price Updated: 10:15 AM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Becton, Dickinson's Debt Overview ↗
 
Via Benzinga
News headline image
(BDX) - Analyzing Becton, Dickinson's Short Interest ↗
 
Via Benzinga
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company? 
Via News Direct
News headline image
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company? ↗
The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. 
Via Benzinga
News headline image
Looking Into Becton's Return On Capital Employed ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Becton, Dickinson ↗
 
Via Benzinga
A Bullish Sign Appears On Becton, Dickinson's Chart ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Becton, Dickinson ↗
 
Via Benzinga
News headline image
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
News headline image
The 7 Best Dividend Growth Stocks for Long-Term Investors ↗
Although passive income is always useful under uncertain times, why not get capital gains through the best dividend growth stocks? 
Via InvestorPlace
News headline image
Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software ↗
Becton Dickinson and Co (NYSE: BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. 
Via Benzinga
News headline image
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO ↗
Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in... 
Via Benzinga
News headline image
2 Medical Stocks to Watch Heading Into 2023 ↗
The two healthcare companies easily outdid the S&P 500 this year. 
Via The Motley Fool
News headline image
Embecta Stock Tumbles On Mixed Q4 Results, Softer Guidance ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Becton, Dickinson ↗
 
Via Benzinga
News headline image
Why Embecta Stock Popped by Nearly 13% Today ↗
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist. 
Via The Motley Fool
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
News headline image
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products 
Via News Direct
Topics Economy
News headline image
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products ↗
Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the... 
Via Benzinga
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Becton Dickinson, Freeport-McMoRan, GXO Logistics And This Mid-Cap ETF On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named iShares Core S&P Mid-Cap ETF (NYSE: IJH), saying that "mid-c 
Via Benzinga
News headline image
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry ↗
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
News headline image
2 Relatively Safe Dividend Stocks to Buy Today and Hold Forever ↗
They already have extensive track records of success, and there's even more on the way. 
Via The Motley Fool
News headline image
2 Top Dividend Kings to Buy for the Long Haul ↗
No matter how much changes, these two healthcare giants keep performing. 
Via The Motley Fool
News headline image
Reliable Passive Income: an Analysis on Dividend Kings ↗
A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
News headline image
NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company ↗
Piper Sandler cut the price target on Becton, Dickinson and Company (NYSE: BDX) from $255 to $245. Piper Sandler analyst Jason Bednar maintained the stock with a Neutral. Becton, Dickinson shares... 
Via Benzinga
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today ↗
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.41% on an annualized basis producing an average annual return of 11.05%. Currently, Becton, Dickinson has a market... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.